Product Name: ErbB3 (693-707)
Product Number: PE-01ART80
| Size: | 200 µg | Price: | 38.00 | |
| 1 mg | $US | 77.00 | ||
| 5 mg | 166.00 |
Peptide Name: ErbB3 (693-707)
Product Use: Services as a blocking peptide for use with the ErbB3-2 rabbit polyclonal antibody (Cat. No.: AB-NK231-3) that is also available from Kinexus.
Peptide Production Method: Solid-phase peptide synthesis
Peptide Origin: Homo sapiens
Peptide Sequence: CSEKANKVLARIFKET
Peptide Modifications N Terminus: Free amino
Peptide Modifications C Terminus: Amide
Peptide Molecular Mass Calculated: 1836.1 Da
Peptide Purity Percent after Synthesis and Purification: >80
Peptide Appearance: White powder
Product Use: Services as a blocking peptide for use with the ErbB3-2 rabbit polyclonal antibody (Cat. No.: AB-NK231-3) that is also available from Kinexus.
Peptide Production Method: Solid-phase peptide synthesis
Peptide Origin: Homo sapiens
Peptide Sequence: CSEKANKVLARIFKET
Peptide Modifications N Terminus: Free amino
Peptide Modifications C Terminus: Amide
Peptide Molecular Mass Calculated: 1836.1 Da
Peptide Purity Percent after Synthesis and Purification: >80
Peptide Appearance: White powder
Peptide Form: Solid
Storage Conditions: -20°C
Related Product 1: ErbB3 pan-specific antibody (Cat. No.: AB-NK231-3)
Storage Conditions: -20°C
Related Product 1: ErbB3 pan-specific antibody (Cat. No.: AB-NK231-3)
Scientific Background: ErbB3 (HER3) is a protein-tyrosine kinase of the TK group and EGFR family. It is a receptor kinase that bind and be activated by NTAK and neuregulins. It has been proposed to be deficient in phosphotransferase activity. While the kinase domain appararently lacks activity but heterodimerizes with other EGFRs permits transduction of growth signals. Phosphorylation of Y1222 and Y1260 induces interaction with PIK3C and PIK3R1. ErbB3 appears to be up-regulated in many cancer, including medulloblastomas, verrucous carcinomas, childhood medulloblastomas, carotid body tumours (CBT), and gestational trophoblastic tumours (GTD).
© Kinexus Bioinformatics Corporation 2017